| Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. | |
| | |
MedLine Citation:
|
PMID: 9169967 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The selective pharmacology of the selective serotonin reuptake inhibitors (SSRIs) results in a lower potential for pharmacodynamic drug interactions relative to other antidepressants such as the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). However, the SSRIs have been implicated in the development of the serotonin syndrome--a potentially life-threatening complication of treatment with psychotropic drugs. The syndrome is produced most often by the concurrent use of two or more drugs that enhance central nervous system serotonin activity and often goes unrecognized because of the varied and nonspecific nature of its clinical features. The serotonin syndrome is characterized by alterations in cognition (disorientation, confusion), behavior (agitation, restlessness), autonomic nervous system function (fever, shivering, diaphoresis, diarrhea), and neuromuscular (ataxia, hyperreflexia, myoclonus) activity. The difference between this syndrome and the occurrence of adverse effects caused by serotonin reuptake inhibitors alone is the clustering of the signs and symptoms, their severity, and their duration. There are important pharmacokinetic interactions between SSRIs and other serotonergic drugs due principally to their effects on the cytochrome P450(CYP) isoenzymes, the potential for which varies widely amongst the SSRI group, which may increase the likelihood of a pharmacodynamic interaction. The exceptionally long washout period required after fluoxetine discontinuation may cause additional problems and/or inconvenience. Patients with serotonin syndrome usually respond to discontinuation of drug therapy and supportive care alone, but they may also require treatment with antiserotonergic agent such as cyproheptadine, methysergide, and/or propranolol. To reduce the occurrence, morbidity, and mortality of the serotonin syndrome, it must be both prevented by prudent pharmacotherapy and given prompt recognition when it is present. |
| | |
Authors:
|
R Lane; D Baldwin |
Related Documents
:
|
2031757 - Which antidepressant? 7272177 - Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor respons... 1609337 - Recent advances in antidepressant drugs. 9533167 - Clinical application of time-dependent sensitization to antidepressant therapy. 15544057 - In vitro evaluation of fixed dose combination tablets of anti-tuberculosis drugs after ... 7664347 - Lipid microspheres for drug delivery from the pharmaceutical viewpoint. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of clinical psychopharmacology Volume: 17 ISSN: 0271-0749 ISO Abbreviation: J Clin Psychopharmacol Publication Date: 1997 Jun |
Date Detail:
|
Created Date: 1997-08-12 Completed Date: 1997-08-12 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 8109496 Medline TA: J Clin Psychopharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 208-21 Citation Subset: IM |
Affiliation:
|
Pfizer Incorporated, New York, New York 10017-5755, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antidepressive Agents
/
adverse effects*,
therapeutic use Autonomic Nervous System Diseases / chemically induced*, therapy Drug Interactions Humans Mental Disorders / chemically induced*, therapy Neuromuscular Diseases / chemically induced*, therapy Serotonin Uptake Inhibitors / adverse effects*, therapeutic use Syndrome |
| Chemical | |
Reg. No./Substance:
|
0/Antidepressive Agents; 0/Serotonin Uptake Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A novel tool to quantify physical activities: ambulatory accelerometry in psychopharmacology.
Next Document: Abuse liability of flunitrazepam.